Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Premature ovarian insufficiency management
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Amenorrhoea may conceal urgent disease
Pelvic pain or bleeding with a positive pregnancy test, haemodynamic instability, severe headache with visual loss, adrenal crisis, acute mania or suicidal intent is not routine premature ovarian insufficiency care.
Action: Assess observations and pregnancy status, examine the relevant system, obtain urgent targeted tests, and use emergency pregnancy, endocrine or mental-health pathways before continuing the elective ovarian-insufficiency work-up.
Overview
Confirm premature ovarian insufficiency accurately, investigate likely causes, provide physiological sex-steroid replacement and contraception advice, and protect fertility, bone, cardiovascular, sexual and psychological health.
Premature ovarian insufficiency describes loss or marked fluctuation of ovarian endocrine and reproductive function before age 40. It is not always irreversible ovarian failure: intermittent follicular activity, ovulation and spontaneous conception can occur. Ask about menstrual change for at least several months, hot flushes, night sweats, vaginal dryness, low libido, sleep, mood and cognition. Establish pregnancy possibility and contraception before interpreting amenorrhoea. The diagnosis can affect identity, relationships and reproductive plans, so explain the work-up before testing and offer results in a setting that allows time for questions.
NICE retains a clear UK diagnostic standard: compatible menopause-associated symptoms, including absent or infrequent periods, plus raised FSH on two samples taken four to six weeks apart in a person under 40. A single high value is insufficient because secretion fluctuates. Routine AMH is not recommended for diagnosis. Combined hormonal contraception and some progestogen regimens suppress gonadotrophins; results obtained during hormonal treatment may be uninterpretable and specialist planning may be needed before interruption. Always exclude pregnancy and investigate a specific alternative such as thyroid or prolactin disease when the presentation supports it.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Confirming suspected POI
A 34-year-old has five months of infrequent periods, night sweats and vaginal dryness. Pregnancy testing is negative and one serum FSH result is elevated. What is the appropriate next diagnostic step?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Causes include ovarian surgery, gonadotoxic chemotherapy or radiotherapy, chromosomal variation, FMR1 premutation, autoimmune disease and rarer metabolic or infectious disorders, but many cases are unexplained. Take a three-generation family history of POI, infertility, fragile-X-associated disorders and relevant genetic disease. The 2024 international guideline recommends chromosomal analysis and specific FMR1 premutation testing for all non-iatrogenic POI, without using age to restrict access, after informed consent and genetic counselling. When the cause remains unknown, test 21-hydroxylase antibodies; a positive result requires endocrine assessment of adrenal function, while a negative test is not repeated unless adrenal-insufficiency symptoms develop. Measure TSH at diagnosis and then every five years or when symptoms arise; routine thyroid-peroxidase or anti-ovarian antibodies are not recommended.
Hormone treatment in POI is replacement, not simply short-term relief of hot flushes. NICE advises offering HRT or a combined hormonal contraceptive unless contraindicated and continuing until at least the usual age of natural menopause. BMS aims for physiological estradiol levels and suggests 75 to 100 micrograms daily by transdermal patch, an estradiol-gel dose equivalent to 2 mg daily, or oral estradiol 2 mg daily. Route is individualised; transdermal estradiol is attractive when VTE risk or higher BMI makes hepatic first-pass effects undesirable. A uterus requires adequate progestogen matched to the oestrogen dose.
Contraception and fertility require separate sentences. HRT does not suppress ovulation reliably and therefore does not prevent pregnancy. If pregnancy is not wanted, add an effective method compatible with the person's health; a 52 mg levonorgestrel IUD can provide contraception and the progestogen component of systemic HRT within its supported interval. An eligible combined hormonal contraceptive can provide both replacement and contraception, although HRT may have more favourable blood-pressure and bone-marker effects. If pregnancy is desired, refer early for reproductive counselling while acknowledging that no intervention reliably restores natural ovarian activity.
Long-term care covers skeleton, cardiovascular health, genitourinary tissue, sexual function and mental wellbeing. The 2024 international guideline recommends baseline DXA at diagnosis where available. If bone density is normal and adequate systemic hormone treatment is taken, repeating DXA within five years has low value; osteoporosis or low density warrants individual reassessment every one to three years. Record blood pressure, smoking, weight, lipids and diabetes status where indicated. Discuss moisturisers, lubricants and vaginal oestrogen for local symptoms. Screen compassionately for anxiety, depression and trauma related to diagnosis, and offer psychological or peer support without presenting distress as inevitable.
Key points
Suspect POI before age 40 when absent or infrequent periods coexist with vasomotor, genitourinary, sleep, mood or sexual symptoms after pregnancy and common secondary causes are considered.
NICE diagnosis requires compatible symptoms and elevated FSH on two blood samples taken four to six weeks apart; do not diagnose from one result or use AMH routinely.
Review previous ovarian surgery, chemotherapy, radiotherapy, infection, autoimmune disease and family history. For non-iatrogenic POI, offer chromosomal analysis and FMR1 premutation testing with consent and genetic counselling; age should not restrict access. Check TSH at diagnosis and screen for 21-hydroxylase antibodies when the cause is unknown; many spontaneous cases remain idiopathic after appropriate investigation.
Offer sex-steroid replacement with HRT or a combined hormonal contraceptive unless contraindicated and continue until at least the usual age of natural menopause.
Aim for physiological replacement: BMS suggests transdermal estradiol 75 to 100 micrograms daily, estradiol gel equivalent to 2 mg daily, or oral estradiol 2 mg daily, individualised to response and risk.
Protect an intact endometrium with proportional progestogen; a cyclic regimen is often useful when intermittent ovarian activity or pregnancy remains relevant.
Aetiology
01
Iatrogenic ovarian injury
Bilateral oophorectomy, pelvic radiotherapy and gonadotoxic systemic treatment can deplete follicles or remove ovarian tissue, with onset shaped by dose, age and pretreatment reserve.
02
Genetic variation
Chromosomal differences and FMR1 premutation can impair follicular development or accelerate depletion, sometimes creating implications for relatives and future offspring.
03
Autoimmune ovarian dysfunction
Autoimmune processes may coexist with thyroid or adrenal disease and can disrupt steroid-producing ovarian tissue even when a specific ovarian antibody is unhelpful.
04
Idiopathic insufficiency
No cause is found after appropriate assessment in many patients, and an idiopathic label should be explained without suggesting that symptoms or consequences are uncertain.
Pathophysiology
1
Follicular depletion
Loss or accelerated attrition of functional follicles reduces inhibin and oestradiol feedback, allowing gonadotrophins to rise while ovarian responsiveness becomes intermittent or absent.
2
Unpredictable residual activity
A small fluctuating follicular pool may resume steroid production or ovulate transiently, explaining why bleeding can return and pregnancy remains possible.
3
Skeletal remodelling
Sustained oestrogen deficiency favours bone resorption over formation during years when peers usually retain ovarian hormone exposure, reducing peak-maintained bone mass.
4
Vascular and tissue effects
Reduced oestrogen exposure alters vasomotor control, genital epithelium and cardiovascular markers, contributing to flushes, dryness and longer-term health concerns.
Clinical features and red flags
Oestrogen-deficiency pattern
Irregular or absent periods with flushes, sweats, vaginal dryness, sleep change or sexual symptoms before 40 raises suspicion after pregnancy is excluded.
Iatrogenic ovarian loss
Bilateral ovarian surgery, pelvic radiotherapy and gonadotoxic systemic treatment can create abrupt or delayed insufficiency and should be linked to pretreatment fertility information.
Autoimmune phenotype
Thyroid disease, vitiligo, Addison features or another autoimmune disorder may accompany POI and directs targeted endocrine and antibody assessment.
Genetic clue
Very early onset, primary amenorrhoea, short stature, dysmorphic features or a family history of POI or fragile-X-associated disease supports genetic referral.
Intermittent ovarian function
Return of bleeding or ovulation does not disprove established POI and is why fertility wishes and contraception must be reviewed repeatedly.
Red flags requiring action
Amenorrhoea with pelvic pain, vaginal bleeding, syncope or shoulder-tip pain requires immediate pregnancy testing and urgent exclusion of ectopic pregnancy.
Hypotension, vomiting, abdominal pain, hyponatraemia or hyperkalaemia with autoimmune features raises concern for adrenal insufficiency and needs urgent endocrine assessment.
Severe headache, visual-field change, galactorrhoea or focal neurological findings requires assessment for pituitary or intracranial disease rather than an ovarian label alone.
Investigations
01Urine or serum hCGFirst step
Why
Exclude pregnancy before diagnosing POI or changing hormone treatment in anyone with reproductive potential.
Interpretation and limitations
A positive result redirects care to pregnancy assessment, urgently when pain, bleeding or instability is present; a negative result does not establish ovarian insufficiency.
02Two serum FSH measurements
Why
Biochemically support POI in a symptomatic person under 40 using the NICE diagnostic approach.
Interpretation and limitations
Both samples should be elevated and taken four to six weeks apart; one result is insufficient and suppression by hormonal treatment can make values misleading.
03Endocrine and autoimmune assessment
Why
Exclude a competing thyroid or prolactin disorder and screen for associated thyroid or adrenal disease after POI is confirmed.
Interpretation and limitations
Measure TSH at diagnosis and repeat every five years or for symptoms. In POI of unknown cause, test 21-hydroxylase antibodies and refer a positive result for endocrine adrenal-function assessment; do not repeat a negative result unless adrenal symptoms arise. Prolactin remains presentation directed.
04Genetic and aetiological tests
Why
Investigate non-iatrogenic POI and identify findings with implications for the patient or relatives.
Interpretation and limitations
Differential diagnosis
01
Pregnancy
Pregnancy remains the most important reversible explanation for amenorrhoea and becomes an emergency differential when pain, bleeding, syncope or instability accompanies it.
02
Hypothalamic amenorrhoea
Energy deficit, high exercise load, stress or chronic illness can suppress gonadotrophins, producing a low-oestrogen state with low or inappropriately normal FSH.
03
Hyperprolactinaemia
Prolactin excess suppresses the reproductive axis and may present with amenorrhoea, galactorrhoea, headache, medicine exposure or visual-field symptoms.
04
Thyroid dysfunction
Both hypo- and hyperthyroidism can alter cycles and mimic mood, temperature and weight symptoms, so testing follows clinical features.
05
Polycystic ovary syndrome
Chronic anovulation can cause infrequent periods, but androgenic features and gonadotrophin patterns differ and oestrogen deficiency is not the defining mechanism.
Management
01ConfirmEstablish POI without shortcutsFirst stepA person under 40 reports sustained menstrual disturbance with compatible symptoms.+
1Exclude pregnancy, document hormone use and assess thyroid, prolactin, hypothalamic, structural and systemic alternatives suggested by the presentation.
2Obtain two elevated FSH measurements four to six weeks apart under conditions in which the result can be interpreted, avoiding routine AMH diagnosis.
3If results conflict, hormonal treatment obscures testing or the presentation is atypical, involve menopause or reproductive medicine expertise before assigning the diagnosis.
02ReplaceRestore hormones and protect the uterusPOI is confirmed and sex-steroid treatment is not contraindicated.+
1Offer physiological HRT or eligible combined hormonal contraception, explaining differences in contraception, route, bleeding and available bone or vascular evidence.
Complications
01
Low bone density
Untreated prolonged oestrogen deficiency reduces bone mineral density and can increase later fragility risk, especially with low weight, smoking or glucocorticoids.
02
Cardiovascular burden
Premature loss of ovarian hormone exposure is associated with less favourable vascular health, making replacement and conventional risk-factor control important.
03
Genitourinary syndrome
Vaginal epithelial thinning, reduced lubrication and urinary tissue change can cause dryness, dyspareunia, dysuria and recurrent urinary symptoms.
04
Fertility impairment
Reduced follicular reserve makes natural conception uncommon and unpredictable, while assisted options and family-building decisions may carry substantial emotional and financial consequences.
05
Psychological distress
Unexpected diagnosis can affect mood, body image, sexuality, relationships and future plans, with some patients needing formal psychological or psychiatric support.
Monitoring and follow-up
Review symptom response, bleeding, adherence, adverse effects, contraception and fertility goals about three months after starting or changing treatment, then at least annually when stable.
Record blood pressure, weight, smoking and relevant lipid or diabetes measures, and address modifiable cardiovascular risk without withholding necessary physiological replacement solely because age-based risk is low.
Arrange DXA at diagnosis where available. If density is normal and adequate hormone treatment is adhered to, repetition within five years has low value; reassess every one to three years when osteoporosis or low density is present, based on individual risk.
Investigate unscheduled, heavy, prolonged or postcoital bleeding using the appropriate HRT and gynaecology pathway rather than repeatedly altering hormones without assessment.
Reassess vaginal comfort, sexual function, mood, sleep and social impact, offering local treatment, psychosexual care, psychological support or specialist referral when needed.
Repeat TSH every five years or sooner for thyroid symptoms; do not repeat a negative 21-hydroxylase-antibody test unless features of adrenal insufficiency develop.
Special situations
POI is not absolute sterility
Ovarian activity can return unpredictably, so both honest fertility counselling and effective contraception remain necessary after diagnosis.
Replacement differs from late HRT
Treatment before the usual menopause age restores hormones that peers generally still produce, changing the clinical balance of benefit and risk.
AMH answers another question
Anti-Müllerian hormone can reflect follicular reserve in selected reproductive settings but NICE does not recommend it as routine confirmation of POI.
Diagnostic standards differ
NICE still requires two raised FSH samples four to six weeks apart in UK care, whereas the 2024 international guideline uses FSH above 25 IU/L and repeats it only when diagnosis is uncertain.
A uterus needs opposition
Physiological estradiol still stimulates endometrium, so absent spontaneous periods never makes progestogen optional when the uterus remains.
Cause may remain unknown
A careful genetic, autoimmune and treatment history can find actionable causes, yet an unrevealing work-up is common and does not invalidate the diagnosis.
Common pitfalls
01
Diagnosing POI after one raised FSH result or from AMH alone despite the NICE two-sample standard.
02
Interpreting suppressed gonadotrophins during combined hormonal contraception as proof that ovarian function is normal.
03
Treating symptoms briefly but omitting replacement through at least the usual age of natural menopause when no contraindication exists.
04
Prescribing systemic oestrogen without adequate progestogen to someone with an intact uterus.
05
Telling a patient that HRT prevents pregnancy or that POI makes spontaneous ovulation impossible.
06
Ordering genetic tests without consent, counselling or a plan for results that may affect relatives.
07
Omitting chromosomal and FMR1 testing in non-iatrogenic POI or 21-hydroxylase antibodies when the cause is unknown because no syndromic phenotype is obvious.
08
Focusing on fertility alone while neglecting bone, cardiovascular, genitourinary, sexual and psychological health.
HRT is not contraception because ovarian activity can recur unpredictably; provide a contraceptive method if pregnancy is not desired, or choose eligible combined hormonal contraception as both replacement and contraception.
Address fertility wishes early, arrange baseline DXA where available, assess cardiovascular risk and psychological wellbeing, and involve reproductive, menopause, genetic or endocrine specialists according to cause and goals.
Rapid virilisation, a pelvic mass or progressive abdominal distension suggests androgen-secreting or structural disease and warrants urgent specialist assessment.
Profound distress, self-harm thoughts, mania, psychosis or inability to stay safe requires same-day mental-health risk assessment alongside sensitive reproductive care.
Offer chromosomal analysis and specific FMR1 premutation testing to all with non-iatrogenic POI after consent and counselling, without an age cut-off. Additional genetic testing is specialist led; a negative work-up often leaves the cause idiopathic.
05Baseline DXA and cardiometabolic assessment
Why
Document consequences and modifiable risk after premature loss of ovarian hormone exposure.
Interpretation and limitations
Use bone density, blood pressure, smoking, weight, lipids and diabetes status to build an individual plan; repeat DXA depends on the initial result, replacement adherence and changing risk.
2Use adequate progestogen with an intact uterus, favouring a sequential approach when intermittent ovarian activity or conception remains relevant.
3Continue replacement until at least the usual natural-menopause age, then reassess future treatment using the person's symptoms and contemporary average-age HRT balance.
03IntegratePlan cause, fertility and long-term healthDiagnosis has been discussed and immediate replacement decisions are underway.+
1For non-iatrogenic POI, arrange consented chromosomal and FMR1 testing; for unknown cause, add 21-hydroxylase antibodies and baseline TSH, with endocrine referral if adrenal antibodies are positive.
2Ask whether pregnancy is desired now, later or not at all; explain intermittent ovarian activity and arrange contraception or timely fertility referral accordingly.
3Assess bone, cardiovascular, genitourinary, sexual and psychological effects and coordinate genetic, endocrine, oncology or specialist bone care where indicated.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
Replaces oestrogen for symptoms and long-term bone and cardiovascular health until at least the usual age of natural menopause.
Transdermal estradiol for POI
Use a transdermal estradiol patch delivering 75 to 100 micrograms per 24 hours, changed at the product-specific interval and titrated to physiological replacement and clinical response.
Add adequate progestogen when a uterus is present; assess unexplained bleeding, hormone-sensitive cancer and thrombotic or hepatic context, and remember that estradiol does not provide contraception.
Provides an alternative physiological replacement route when transdermal patches are unsuitable or not preferred.
Oral or gel estradiol for POI
BMS suggests oral estradiol 2 mg once daily or an estradiol-gel regimen equivalent to 2 mg daily, adjusted for the chosen product and response.
Oral oestrogen has hepatic first-pass effects; reconcile migraine, VTE risk, liver disease and adherence, and pair treatment with proportional endometrial protection.
Opposes systemic oestrogen in an intact uterus and permits a predictable withdrawal bleed during cyclic replacement.
Micronised progesterone with estradiol
Use 200 mg orally at bedtime for 12 to 14 days of each 28-day cycle when a sequential regimen is selected.
Take away from food, warn about drowsiness or dizziness, check product excipients, and obtain specialist advice when oestrogen doses or bleeding patterns require stronger protection.
At the usual age of natural menopause, review whether to continue, change or stop HRT using the contemporary balance for that age rather than stopping automatically on a birthday.